Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
NNZ-2591 in Prader-Willi syndrome
Investor Information
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
Home
>
Investor Information
>
Investor presentations, audio, video
Font Smaller
Font larger
Print Page
Investor presentations, audio, video
24-Jun-2022
AusBiz interview 22 June 2022
30-May-2022
AGM Chairman's Address & CEO Presentation
9-May-2022
Acadia Q1 2022 earnings call transcript
4-Apr-2022
Australian Financial Review article 4 Apr 2022
25-Feb-2022
Investor webinar, 25 February 2022
10-Dec-2021
AusBiz interview 8 December 2021
2-Jul-2021
Peak TV interview 2 July 2021
29-Jun-2021
MST Access Australian Micro & Small Caps Conference 2021 15 June 2021